- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
AptarGroup Inc(ATR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ATR
11/13/2026: ATR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
AptarGroup Inc is a global supplier of precision dispensing, sealing, and drug delivery systems operating across the pharmaceutical, beauty, and consumer markets. The company's primary strength lies in its high-margin Pharma segment, which features sticky customer relationships and proprietary respiratory and nasal delivery technologies. Its core investment narrative centers on secular healthcare growth and specialized drug delivery innovations, balanced against risks like raw material inflation and valuation sensitivities. The stock suits dividend-conscious and low-risk investors seeking stable industrial-healthcare exposure, with ongoing watch points including pharmaceutical pipeline approvals and raw material cost trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers reliable mid-single-digit expansion with upside from pharma innovation, though it lacks hyper-growth tech characteristics. |
| Momentum investor | Strong fit while signal remains positive | Suitable when technical breakouts align with positive earnings surprises and strong pharmaceutical volume updates. |
| Value investor | Mixed fit | Trades at a moderate premium valuation multiple due to its high-quality pharma franchise and earnings stability. |
| Dividend investor | Strong fit | AptarGroup features a dependable dividend payout history with regular annual increases and stable cash flows. |
| Low-risk investor | Strong fit | Exhibits lower cyclical volatility than traditional commodity packaging companies thanks to its defensive pharmaceutical exposure. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock experiences moderate price fluctuations driven by broader market shifts and raw material cost reports. |
| Valuation risk | Medium / high | Shares often command a premium earnings multiple relative to basic packaging peers, leaving little room for earnings misses. |
| Competition risk (specialized packaging and drug delivery) | Medium | Rival packaging and device manufacturers continuously vie for lucrative pharma and beauty contracts. |
| Business quality | Strong | AptarGroup possesses a high-quality franchise backed by proprietary medical device designs and sticky customer relationships. |
| Dividend income | Low | Dividend payouts are safe and well-covered by cash flows, though the current yield is modest. |
| Execution risk | Medium | Successful integration of recent medical acquisitions and scaling new pharma devices are crucial for meeting growth targets. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.07B USD | Price to earnings Ratio 34.56 | 1Y Target Price 163.88 |
Price to earnings Ratio 34.56 | 1Y Target Price 163.88 | ||
Volume (30-day avg) 536.4K shares | Beta 0.32 | 52 Weeks Range 110.17 - 148.11 | Updated Date 11/15/2026 |
52 Weeks Range 110.17 - 148.11 | Updated Date 11/15/2026 | ||
Dividends yield (FY) 1.35% | Basic EPS (TTM) 4.14 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 60.0%
- Active BUY / eligible
- 3 / 5
- 30-Day BUY Count Change
- +1
Eligible universe: 5 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -6.21% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Pharma | Nasal spray pumps, metered-dose inhaler valves, ophthalmic dispensers, and injectable components. | This is the company's profit engine, generating high margins from essential prescription and consumer healthcare drug delivery systems. |
| Beauty | Fine mist sprayers, lotion pumps, airless systems, and cosmetic closures. | Provides steady cash flow tied to global prestige and mass cosmetics, fragrance, and skincare brand demands. |
| Closures | Dispensing and non-dispensing caps for food, beverage, home care, and personal care packaging. | Offers high-volume baseline revenue linked to everyday consumer staples and household goods. |
| Geography (Europe, North America, Asia) | Global manufacturing footprint spanning Europe, the United States, China, and other international markets. | Geographic diversification helps insulate the business from localized economic downturns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 1.46 | Actual 1.52 |
Profitability
Profit Margin 6.7% | Operating Margin (TTM) 12.38% |
Management Effectiveness
Return on Assets (TTM) 6.05% | Return on Equity (TTM) 9.79% |
Valuation
Trailing PE 34.56 | Forward PE 23.58 | Enterprise Value 10.28B | Price to Sales(TTM) 2.27 |
Enterprise Value 10.28B | Price to Sales(TTM) 2.27 | ||
Enterprise Value to Revenue 2.57 | Enterprise Value to EBITDA 14 | Shares Outstanding 63.39M | Shares Floating 62.78M |
Shares Outstanding 63.39M | Shares Floating 62.78M | ||
Percent Insiders 1.67 | Percent Institutions 98.65 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

